John Doux - 10 Jun 2026 Form 4 Insider Report for PALVELLA THERAPEUTICS, INC. (PVLA)

Reporting relationship: Director
Issuer ticker: PVLA
Reported as of: 10 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 12 Jun 2026, 16:06:07 UTC
Prior SEC filing: 15 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Kathleen A. McGowan, Attorney-in-Fact

Key filing fact

John Doux filed Form 4 for PALVELLA THERAPEUTICS, INC. (PVLA) on 12 Jun 2026.

Key facts

This page summarizes John Doux's Form 4 filing for PALVELLA THERAPEUTICS, INC. (PVLA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 12 Jun 2026, 16:06.

Change

Previous filing in this sequence was filed on 15 Apr 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001912574 Primary reporting owner

Doux John

Relationship: Director
Address: C/O PALVELLA THERAPEUTICS, INC., 353 W. LANCASTER AVENUE, SUITE 200, WAYNE
Signature: /s/ Kathleen A. McGowan, Attorney-in-Fact
Signature date: 12 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PVLA transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +3,000
Change %
Price: $0.000000^*
Shares after: 3,000
Date: 10 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,000
Exercise price: $102.19
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares subject to this option shall vest upon the earlier of (i) the first anniversary of the grant date or (ii) the date of the Issuer's next annual meeting of stockholders following the grant date, subject in each case to the Reporting Person's continued service through the applicable vesting date.